CEN BIOTECH, INC.: 10-Q filed 2021-05-12
What CEN BIOTECH, INC. reported in its quarterly report filed 2021-05-12 (fiscal Q1 2021): 23 published measures, 46 facts as tagged in accession 0001437749-21-011851.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-05-12
- Fiscal period
- fiscal Q1 2021
- Accession
- 0001437749-21-011851 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CEN BIOTECH, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 6,214,081 | USD | |
| At 2020-12-31 | 6,314,142 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 16,677,593 | USD | |
| At 2020-12-31 | 16,305,859 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | -10,463,512 | USD | |
| At 2020-12-31 | -9,991,717 | USD | |
| At 2020-03-31 | -26,606,224 | USD | |
| At 2019-12-31 | -25,535,162 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 780 | USD | |
| At 2020-12-31 | 1,908 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -623,035 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -1,300,112 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -61,128 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -180,213 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | -27,683,562 | USD | |
| At 2020-12-31 | -27,060,527 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 75,750 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 196,650 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -344,840 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -530,750 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 18,681 | USD | |
| At 2020-12-31 | 19,809 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 15,069,083 | USD | |
| At 2020-12-31 | 14,705,757 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 221,001 | USD | |
| At 2020-12-31 | 190,716 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 4,849,944 | USD | |
| At 2020-12-31 | 4,956,147 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 344,840 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 530,750 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 27,610,732 | shares | |
| At 2020-12-31 | 27,557,363 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 17,220,050 | USD | |
| At 2020-12-31 | 17,068,810 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 170,169 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 4,849,944 | USD | |
| At 2020-12-31 | 4,956,147 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 658,833 | USD | |
| At 2020-12-31 | 641,023 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 237,890 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 302,900 | USD | 91 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 4,596 | USD | 91 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 106,203 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 106,203 | USD | 91 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -278,195 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -769,362 | USD | 91 |
Inspect the source
- Entity
- CEN BIOTECH, INC. / CIK 0001653821
- Captured
- SEC response SHA-256
097c84c6c785c728d94a8aab95d5185c6c0595b9a921b7610327e115a19292be
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001653821.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))